Drug company pulls out of Chinese lawsuit over diabetes drugBMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7464.476-f (Published 26 August 2004) Cite this as: BMJ 2004;329:476
- Jane Parry
- Hong Kong
In a move that highlights the struggle between multinational drug companies and manufacturers of generic drugs, GlaxoSmithKline has withdrawn from legal action in China to defend the formulation patent on rosiglitazone, the major component of its antidiabetes drug Avandia.
The large multinational companies, such as GlaxoSmithKline, are trying to get a foothold in the Chinese market while preventing competition from local copies of their products. Rather than just continue to breach copyright the Chinese companies are trying to secure the right to make the drugs legally.
Chris Hunter-Ward, the UK spokesman for GlaxoSmithKline, said: “There had been previous disclosures of some of the elements …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial